Kari L Kendra

10PUBLICATIONS
90CO-AUTHORS
Predictive and prognostic markersMolecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

|Apr 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

|Jan 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial.

Kari L Kendra, Shay L Bellasea, Zeynep Eroglu

|Aug 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.

Kari L Kendra, Shay L Bellasea, Zeynep Eroglu

|Aug 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.

Kari L Kendra, Shay L Bellasea, Zeynep Eroglu

|Nov 28, 2023
Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.

Himanshu Savardekar, Carter Allen, Hyeongseon Jeon

Pageof 2

Frequent Collaborators

7 joint publications

Antoni Ribas

4 joint publications

Michael C Wu

4 joint publications

Sapna P Patel

4 joint publications

Egmidio Medina